Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis
Crohn’s & Colitis 360 · 05.10.2026 · 8 (4)
DOI: 10.1093/crocol/otag086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn’s & Colitis 360, online erschienen am 30.10.2026. Verfasst von Youssef Hafez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Louis University School of Medicine, Saint Louis, MO, United States. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute.
Abstract (Originalsprache)
Background
Inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS) frequently coexist and share overlapping immune pathways, yet comparative real-world outcomes between IL-12/23 or IL-23 inhibitors and Janus kinase (JAK) inhibitors in this population remain poorly defined.
Methods
We conducted a retrospective cohort study using a large, multicenter, real-world dataset. Adults (≥16 years) with IBD and HS who initiated an IL-12/23 or IL-23 inhibitor after anti-TNF therapy or a JAK inhibitor were included; patients with prior exposure to the opposing drug class were excluded. Propensity score matching (1:1) yielded 150 patients per cohort. Outcomes from 30-365 days included acute care utilization, corticosteroid use, IBD complications, and overall and hidradenitis-specific antibiotic use.
Results
After propensity score matching, 300 patients were included (150 per cohort; mean age 38 years; 75.3% female). Rates of emergency department visits or hospitalization were similar between groups (RR 1.20, 95% CI, 0.82-1.77). Corticosteroid use risk was numerically higher in the IL-12/23 or IL-23 cohort (RR 1.20, 95% CI, 0.98-1.46). IBD-related complications did not differ significantly (RR 1.06, 95% CI, 0.58-1.93). Overall antibiotic use was comparable, while hidradenitis-specific antibiotic use was higher in the IL-12/23 or IL-23 cohort (RR 1.47, 95% CI, 1.11-1.95).
Conclusions
In this real-world analysis, IL-12/23 or IL-23 inhibitor therapy was associated with higher hidradenitis-specific antibiotic use and numerically greater but statistically nonsignificant corticosteroid exposure, while hospitalization and IBD-related complications were comparable. These findings should be interpreted cautiously given the absence of validated disease-activity measures; prospective studies are needed to inform optimal therapeutic selection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Louis University School of Medicine, Saint Louis, MO, United States.
- Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, United States.
- Department of Physiology, Faculty of Medicine and Nursing, University of Basque Country UPV/EHU, Leioa, Vizcaya, Spain.
ORCID-Profile: Youssef Hafez, Ali Osman, Wing-Kin Syn, Manar Shmais
Förderung
- National Institutes of Health
- Wellcome Trust
- Howard Hughes Medical Institute
Zitieren
APA
Hafez, Y., Osman, A., Syn, W. K., & Shmais, M. (2026). Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis. Crohn’s & Colitis 360, 8(4). https://doi.org/10.1093/crocol/otag086
Vancouver
Hafez Y, Osman A, Syn WK, Shmais M. Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis. Crohn’s & Colitis 360. 2026;8(4). doi:10.1093/crocol/otag086
BibTeX
@article{Hafez2026,
author = {Hafez, Youssef and Osman, Ali and Syn, Wing-Kin and Shmais, Manar},
title = {Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis},
journal = {Crohn’s & Colitis 360},
year = {2026},
volume = {8},
number = {4},
doi = {10.1093/crocol/otag086}
}
EUVIMED